AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02297698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
Study NCT04332965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical Periodontal Treatment
Description: Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.
Study NCT00891917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ubiquinol-10 Syrup
Description: 10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
Study NCT00891917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: syrup (placebo)
Description: syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
Study NCT00465465 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: i.d. injection
Study NCT04602975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 10 µg Adjuvanted
Description: Intramuscular injection of experimental vaccine (adjuvanted 10 µg)
Study NCT04602975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 10 µg
Description: Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)
Study NCT04602975 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection Adjuvanted Placebo
Description: Intramuscular injection of Placebo with alhydrogel
Study NCT04602975 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection Placebo
Description: Intramuscular injection of the not adjuvanted Placebo
Study NCT04602975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 2 µg Adjuvanted
Description: Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
Study NCT02732119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: supplied in 25 mg tablets taken orally, daily for 28 day cycle
Study NCT02648776 — intervention group
Intervention type: DRUG
Intervention: Exposure to sedative-hypnotic drugs
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
Study NCT03733002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AngongNiuhuang pill
Description: This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
Study NCT03733002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AngongNiuhuang pill
Description: This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
Study NCT03733002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: The other treatments according to guidelines for standard treatment of acute ischemic stroke.
Study NCT03733002 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: The other treatments according to guidelines for standard treatment of acute ischemic stroke.
Study NCT03719521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based package of integrated HIV, SRH and general health services
Description: HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
Study NCT03719521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based package of integrated HIV, SRH and general health services
Description: HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
Study NCT02468115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS410
Description: Single fixed IV dose of VIS410
Study NCT02468115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose of placebo
Study NCT00679315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfuzosin hydrochloride XL 10mg
Description: One tablet to be taken daily after a meal before bedtime for 8 weeks.
Study NCT00679315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet to be taken daily after a meal before bedtime for 8 weeks.
Study NCT00964860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glide dental floss
Description: Glide waxed dental floss
Study NCT01612481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest radiography
Description: surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
Study NCT01612481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest CT
Description: surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
Study NCT00736684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Femoral Nail AntirotationTM (PFNA)
Description: intramedullary nailing
Study NCT00736684 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gamma Nail 3TM (Gamma3)
Description: intramedullary nailing
Study NCT04602975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 2 µg
Description: Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
Study NCT01154192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
Study NCT01154192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin (r-hCG)
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
Study NCT00733811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) and Deferoxamine (DFO)
Description: Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
Study NCT00733811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone (DFP)
Description: DFP alone at 75 mg/kg divided into three oral daily doses
Study NCT01910012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study NCT02637661 — intervention group
Intervention type: OTHER
Intervention: earlobe crease positive
Study NCT02637661 — intervention group
Intervention type: OTHER
Intervention: earlobe crease negative
Study NCT00837473 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
Description: Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
Study NCT04610879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
Study NCT04610879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
Study NCT04610879 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent based sleep (PBS) intervention
Description: The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
Study NCT02594085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 1
Description: Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
Study NCT02594085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 2
Description: Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
Study NCT01444118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)
Description: Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
Study NCT02594085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 3
Description: Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
Study NCT02594085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 4
Description: Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
Study NCT02594085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patch 5
Description: Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
Study NCT02594085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 6
Description: Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
Study NCT00641459 — intervention group
Intervention type: OTHER
Intervention: Observational BPSD treatment study
Description: Observational BPSD treatment study
Study NCT02985684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® CARDIOFORM ASD Occluder
Description: Percutaneous Atrial Septal Defect Closure
Study NCT06063525 — intervention group
Intervention type: OTHER
Intervention: Structural anatomy
Description: images acquired with 3T MRI system with 32 channel head coil
Study NCT02430285 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Ultrasound
Description: Endoscopic Ultrasound
Study NCT02430285 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Olympus 180 series echoendoscope
Study NCT01867424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eovist
Description: 0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
Study NCT01246401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-Release Naltrexone
Description: Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
Study NCT01935570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium chloride (ChronoMag Smart Tablet®)
Study NCT01935570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium carbonate (Mag2® Tablet)
Study NCT01789255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT01789255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO
Study NCT01789255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study NCT01789255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT01789255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01789255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00863317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: 4mg granules daily for 14 days
Study NCT00863317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: table sugar as placebo daily for 14 days
Study NCT03277794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOP-C
Description: Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
Study NCT03277794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transitional Case Management Only
Description: Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
Study NCT02756741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALBUMIN
Description: Albumin in two different doses
Study NCT02756741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALBUMIN
Description: Albumin in two different doses
Study NCT03573804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone to Supine MRI
Description: The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
Study NCT01131078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab [Avastin]
Description: Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
Study NCT01246401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Extended-Release Naltrexone
Description: Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
Study NCT01131078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.
Study NCT01131078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was administered as a 240 mg/m\^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
Study NCT05528471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: To compare an iso-caloric, low fructose diet (\~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (\~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
Study NCT00044967 — intervention group
Intervention type: GENETIC
Intervention: microsatellite instability analysis
Study NCT01123967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proactive outreach (PRO)
Description: a mailed invitation letter followed by telephone outreach
Study NCT01123967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone counseling (TC)
Description: free telephone counseling
Study NCT01123967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Description: free nicotine replacement therapy (NRT)
Study NCT01123967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (UC)
Description: nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
Study NCT01021059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-15
Description: rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
Study NCT00507130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 0.3 mg/kg
Description: MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
Study NCT00507130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 1 mg/kg
Description: MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
Study NCT01518309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimavanserin tartrate (ACP-103)
Description: Tablets taken once daily by mouth at 20, 40, or 60 mg doses
Study NCT01735097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E (200 mg, soft capsule)
Study NCT01735097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E (200 mg, soft capsule)
Study NCT01735097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nigella sativa
Description: Nigella sativa (200 mg, soft capsule)
Study NCT01735097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
Study NCT00944580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
Description: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
Study NCT03418376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation
Description: The supplementation protocol of β-alanine (Etixx® Omega Pharma Belgium NV) involves oral intake of 4 x 800mg (3.2g/day29, 43) daily with at least 2h apart of slow-release β-alanine during the first 12 weeks. After this loading period, subjects will receive a maintenance dose of 2 x 800mg (1.6g/day) β-alanine for the remaining study duration.
Study NCT03418376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: The exercise training program (6 months) involves 3 week cycles (week I-III). During week I, subjects will perform high volume moderate intensity cardiovascular cycle training (3x/week). Twice a week, subjects perform 3h training sessions (70-80% HRmax\*) and once a week a 1.5h session will be executed (80-90% HRmax). During week II, subjects will perform low volume maximum intensity interval cycle training (3/w). High intensity interval cycle training (HIIT) will consist of 3x maximal sprints (90-100% HRmax) of 1.5min, interspersed with 3min rest intervals. A 5min standardized warming up and 5min cooling down will be performed. Week III involves a recovery week where subjects will perform one training session of 1.5h at an exercise intensity of 70-80% HRmax and one session of HIIT.
Study NCT03418376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise intervention
Description: The exercise training program (6 months) involves 3 week cycles (week I-III). During week I, subjects will perform high volume moderate intensity cardiovascular cycle training (3x/week). Twice a week, subjects perform 3h training sessions (70-80% HRmax\*) and once a week a 1.5h session will be executed (80-90% HRmax). During week II, subjects will perform low volume maximum intensity interval cycle training (3/w). High intensity interval cycle training (HIIT) will consist of 3x maximal sprints (90-100% HRmax) of 1.5min, interspersed with 3min rest intervals. A 5min standardized warming up and 5min cooling down will be performed. Week III involves a recovery week where subjects will perform one training session of 1.5h at an exercise intensity of 70-80% HRmax and one session of HIIT.